{"id":"ac-170-0","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL1000","moleculeType":"Small molecule","molecularWeight":"388.90"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the SGLT2 receptor, AC-170 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.","oneSentence":"AC-170 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:58:47.637Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07461727","phase":"PHASE1","title":"An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-10","conditions":"Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Liver Metastases","enrollment":15},{"nctId":"NCT05660083","phase":"PHASE2","title":"Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2023-01-12","conditions":"HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma","enrollment":36},{"nctId":"NCT06120673","phase":"PHASE3","title":"REmission in Membranous Nephropathy International Trial (REMIT)","status":"WITHDRAWN","sponsor":"The University of Queensland","startDate":"2025-10-31","conditions":"Primary Membranous Nephropathy","enrollment":""},{"nctId":"NCT04323566","phase":"PHASE2","title":"Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System Involvement","status":"ENROLLING_BY_INVITATION","sponsor":"Uppsala University Hospital","startDate":"2022-05-01","conditions":"Obsessive-Compulsive Disorder, Obsessive-Compulsive Behavior, Schizophrenia","enrollment":40},{"nctId":"NCT06126991","phase":"PHASE1, PHASE2","title":"Organ Protective Effect of Cetirizine In Patients With Severe Burns","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2024-01-23","conditions":"Burns","enrollment":32},{"nctId":"NCT03047278","phase":"PHASE4","title":"Transporters for Organic Cations and Glycemic Control in Patients With Neuropathic Pain.","status":"COMPLETED","sponsor":"Natalia Valadares de Moraes","startDate":"2015-11-01","conditions":"Neuropathic Pain, Type 2 Diabetes Mellitus, Diabetic Neuropathy, Painful","enrollment":29},{"nctId":"NCT01881113","phase":"PHASE3","title":"A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2013-06","conditions":"Allergic Conjunctivitis","enrollment":101},{"nctId":"NCT01551056","phase":"PHASE3","title":"A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2012-03","conditions":"Allergic Conjunctivitis","enrollment":91},{"nctId":"NCT01685242","phase":"PHASE3","title":"A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2012-09","conditions":"Allergic Conjunctivitis","enrollment":100},{"nctId":"NCT02132169","phase":"PHASE3","title":"A Multi-Center Study Evaluating the Safety of AC-170 0.24%","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2014-05","conditions":"Atopic Disease (Including Allergic Conjunctivitis)","enrollment":512},{"nctId":"NCT01332188","phase":"PHASE2, PHASE3","title":"Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2011-04","conditions":"Allergic Conjunctivitis","enrollment":101},{"nctId":"NCT00866788","phase":"PHASE2","title":"A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2009-03","conditions":"Chronic Idiopathic Urticaria","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["1 drop in each eye 2 times daily for up to 6 weeks"],"phase":"phase_3","status":"active","brandName":"AC-170 0%","genericName":"AC-170 0%","companyName":"Aciex Therapeutics, Inc.","companyId":"aciex-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AC-170 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}